Imidazopyridine derivatives which inhibit the secretion of gastric acid
View Patent ↗The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH 2 COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.
1. A method for the treatment of a condition selected from gastric acid related diseases, gastrointestinal inflammatory diseases, symptomatic GERD, erosive esophagitis, peptic ulcer disease, heartburn, regurgitation, acid reflux diseases and nausea, comprising administering, to a subject in need thereof, a therapeutically effective amount of a substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof:
where R is —CH 2 COOH or —COOH.
2. The method according to claim 1 , wherein the compound of formula I is 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 , wherein the compound of formula I is 4-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-4-oxobutanoic acid or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 , wherein the substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof
where R is —CH 2 COOH or —COOH, is in combination with a pharmaceutically acceptable diluent or carrier.
5. A method for reducing gastric acid secretion, the method comprising administering, to a subject in need thereof, a therapeutically effective amount of a substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof:
where R is —CH 2 COOH or —COOH.